𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A tale on animal models of Parkinson's disease

✍ Scribed by Erwan Bezard; Serge Przedborski

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
147 KB
Volume
26
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Parkinson's disease is a neurodegenerative disorder whose cardinal manifestations are due primarily to a profound deficit in brain dopamine. Since the 1980s, several therapeutic strategies have been discovered to treat the symptoms of this neurological disorder, but as of yet, none halts or retards the neurodegenerative process. In an attempt to shed light on the neurobiology of Parkinson's disease, a number of experimental models have been developed, especially during the last 25 years. They come essentially in 3 flavors: pharmacological (eg, reserpine), toxic (eg, 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine), and genetic (eg, transgenic synuclein mice). These models can also be recast as etiologic, pathogenic, and symptomatic/pathophysiologic, as each may contribute to our understanding of the cause, the mechanisms, and the treatment of Parkinson's disease. In this review, we will discuss the question of Parkinson's disease models, starting from the period when this journal was born to today. During this journey of 25 years, we will discuss both the significant contributions of the Parkinson's disease models and hurdles that remain to be overcome to one day cure this neurological disease. © 2011 Movement Disorder Society

📜 SIMILAR VOLUMES

Animal models of Parkinson's disease
Animal models of Parkinson's disease
✍ Ranjita Betarbet; Todd B. Sherer; J. Timothy Greenamyre 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 272 KB 👁 1 views

## Abstract Animal models are important tools in experimental medical science to better understand pathogenesis of human diseases. Once developed, these models can be exploited to test therapeutic approaches for treating functional disturbances observed in the disease of interest. On the basis of e

New animal models of Parkinson's disease
New animal models of Parkinson's disease
✍ Benjamin Dehay; Erwan Bezard 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB

## Abstract ## Background: Parkinson's disease is a progressive neurodegenerative disorder mainly characterized by the loss of dopaminergic neurons from the substantia nigra pars compacta and the presence, in the affected brain regions, of protein inclusions named Lewy Bodies. Despite the fact tha

Models of Parkinson's disease
Models of Parkinson's disease
✍ Michael Orth; Sarah J. Tabrizi 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

## Abstract Parkinson's disease (PD) is a heterogenous disease likely to be caused by more than one specific aetiological factor. In rare familial cases of PD with similar clinical features to the idiopathic form of the disease, the underlying genetic cause has been identified. These PD‐associated

Synergistic antidyskinetic effects of to
Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease
✍ Christopher Kobylecki; Michael P. Hill; Alan R. Crossman; Paula Ravenscroft 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 705 KB

## Abstract L‐Dopa‐induced dyskinesia in patients with Parkinson's disease can be alleviated by amantadine, an antagonist at __N__‐methyl‐D‐aspartate glutamate receptors. The antiepileptic drug topiramate, which blocks α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptors, has also been sh